SCHEMBL11900501

SCHEMBL11900501

Nc1ccc(F)cc1Nc1cnccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
KDM4E B2RXH2 1/20 0.45
KMT2A Q03164 2/20 0.42
MAPK10 P53779 2/20 0.40
HDAC3 O15379 4/20 0.38
NCOR1 O75376 1/20 0.38
HDAC1 Q13547 5/20 0.38
CDK8 P49336 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
CDK9 P50750 1/20 0.38
CDK5 Q00535 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
HDAC2 Q92769 4/20 0.35
HDAC8 Q9BY41 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11900768 0.79 MEN1 (0.55) ALDH1A1KDM4EKMT2AMAPK10HDAC3
SCHEMBL22232338 0.79 KDM4E (0.37) ALDH1A1HPGDKDM4EKMT2AMAPK10
SCHEMBL31723226 0.79 KDM4E (0.37) ALDH1A1HPGDKDM4EKMT2AMAPK10
SCHEMBL11900543 0.79 MKNK1 (0.43) ALDH1A1KMT2AMAPK10HDAC3NCOR1
SCHEMBL16038144 0.78 MAPK10 (0.41) ALDH1A1HPGDKDM4EKMT2AMAPK10
SCHEMBL11901790 0.78 MKNK1 (0.43) ALDH1A1MAPK10GSK3ACDK9CDK5
SCHEMBL11901512 0.76 ALDH1A1 (0.49) ALDH1A1HPGDKDM4EKMT2AMEN1
SCHEMBL2503575 0.75 HDAC1 (0.46) ALDH1A1KDM4EKMT2AHDAC3NCOR1
SCHEMBL22971330 0.75 HPGD (0.47) ALDH1A1HPGDKDM4EKMT2AMAPK10
SCHEMBL16089615 0.75 MAPK10 (0.41) ALDH1A1HPGDKDM4EKMT2AMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 ALDH1A1 1680/4885HPGD 298/4885KDM4E 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.